NextGen geneCore Somatic Basic HRD Score panel
NextGen geneCore Somatic Basic HRD Score panel** Price
Brief Details
What Is the NextGen geneCore Somatic Basic HRD Score Panel?
A NextGen geneCore Somatic Basic HRD Score Panel is a specialised genetic test performed on tumour tissue to measure homologous recombination deficiency (HRD) in cancer cells. This advanced test uses next-generation sequencing (NGS) technology to analyse your tumour's DNA and identify specific genetic patterns that indicate whether your cancer cells have difficulty repairing damaged DNA.
The test helps determine if your cancer is likely to respond well to targeted treatments called PARP inhibitors, making it a valuable tool for personalised cancer care.
What Does the NextGen geneCore Somatic Basic HRD Score Panel Measure?
The NextGen geneCore Somatic Basic HRD Score Panel evaluates several important aspects of your tumour's genetic makeup:
- Genomic instability patterns: The test looks for specific "genomic scars" left behind by faulty DNA repair mechanisms.
- Loss of heterozygosity (LOH): Areas where genetic material has been lost during cell division
- Telomeric allelic imbalance (TAI): Imbalances at chromosome ends that indicate repair problems
- Large-scale state transitions (LST): Major changes in chromosome structure
- HRD score calculation: A numerical score that indicates the overall level of homologous recombination deficiency
- PARP inhibitor treatment eligibility: Whether your tumour is likely to respond to this targeted therapy
NextGen geneCore Somatic Basic HRD Score Panel: Who Needs It and Why It's Done
What Symptoms May Call for a NextGen geneCore Somatic Basic HRD Score Panel?
The NextGen geneCore Somatic Basic HRD Score Panel is ordered after cancer diagnosis, not based on specific symptoms. However, the original symptoms that led to the cancer diagnosis may include:
- Ovarian cancer symptoms: Persistent bloating, pelvic pain, difficulty eating, feeling full quickly.
Who Should Get a NextGen geneCore Somatic Basic HRD Score Panel?
This specialised test is recommended for specific cancer patients where HRD status influences treatment decisions:
- Patients with advanced ovarian cancer: Particularly high-grade serous ovarian carcinoma.
- Cancer patients being considered for PARP inhibitor therapy: To determine treatment suitability.
Why Is a NextGen geneCore Somatic Basic HRD Score Panel Done?
This test guides personalised cancer treatment by identifying patients who are most likely to benefit from PARP inhibitor drugs, leading to more effective treatment outcomes and improved quality of life.
Importance of a NextGen geneCore Somatic Basic HRD Score Panel
The NextGen geneCore Somatic Basic HRD Score Panel represents a significant advancement in precision oncology. By identifying tumours with defective DNA repair mechanisms, this test enables doctors to select the most appropriate targeted therapies for each patient.
When cancer cells cannot properly repair their DNA damage, they become vulnerable to PARP inhibitor drugs that exploit this weakness. This targeted approach can effectively destroy cancer cells while minimising harm to healthy tissue. For patients with HRD-positive tumours, this translates to better treatment responses, longer remission periods, and improved overall outcomes compared to traditional chemotherapy approaches.
NextGen geneCore Somatic Basic HRD Score Panel Booking & Reports – Metropolis Healthcare India
How to Book a NextGen geneCore Somatic Basic HRD Score Panel?
- Simple Online Booking
Booking can be done through the Metropolis Healthcare App or website. Select the 'NextGen geneCore Somatic Basic HRD Score Panel', choose a convenient time slot, and visit your nearest Metropolis Lab.
- Sample Tracking Updates
Stay informed at every step. From collection to testing, you can track your sample directly through the Metropolis Healthcare website.
- Accurate Laboratory Testing
Your sample is processed at our NABL & CAP accredited laboratories, where expert technicians ensure accurate results.
- Quick & Easy Reports
Receive your test reports promptly via email, WhatsApp, or by downloading them directly from the Metropolis Healthcare website or app.
Is Home Sample Collection for the NextGen geneCore Somatic Basic HRD Score Panel Available Near You?
No, home sample collection is not available for the NextGen geneCore Somatic Basic HRD Score Panel. This test requires a tumour tissue sample that is typically collected during your biopsy or surgery at the hospital. Once your tissue sample is available in the formalin-fixed paraffin-embedded (FFPE) block format, it can be sent to a Metropolis Healthcare NABL and CAP accedited laboratory for analysis.
How Long Does It Take to Get a NextGen geneCore Somatic Basic HRD Score Panel Report?
Reports are usually available within 20 days once the sample reaches the pathology lab.
Note: Reporting time may vary depending on your location.
Where Can I See or Get NextGen geneCore Somatic Basic HRD Score Panel Results?
Test results from Metropolis Healthcare can be accessed through multiple convenient channels. You can log in to the Metropolis website using your credentials or use the Metropolis Healthcare App to view and download your reports. Additionally, test reports are sent via email or WhatsApp, and you also have the option to collect a physical copy directly from the lab.
Interpreting NextGen geneCore Somatic Basic HRD Score Panel Results
HRD is measured mainly using genomic instability metrics that reflect the characteristic DNA repair defects. The following table explains what your HRD score results may indicate for your treatment options:
|
Parameter |
HRD-Positive (High Score) |
HRD-Negative (Low Score) |
|
HRD Score |
Indicates significant genomic instability and faulty DNA repair; likely to respond to PARP inhibitors |
Indicates a functional DNA repair system; PARP inhibitors may be less effective. |
Conditions that May Affect NextGen geneCore Somatic Basic HRD Score Panel Accuracy
Several factors can influence the accuracy of your HRD score results and should be considered:
- Tissue sample quality: Poor fixation or degraded tissue can affect DNA analysis accuracy.
- Tumour cell percentage: Samples with low tumour content may yield inconclusive results.
- Previous chemotherapy treatments: Some treatments can alter genomic patterns in tumour tissue.
- Sample age and storage conditions: Older samples or improper storage may impact DNA quality.
- Tumour heterogeneity: Different areas of the same tumour may show varying HRD patterns.
- Technical factors: Laboratory processing conditions and sequencing depth can influence results.
How Is a NextGen geneCore Somatic Basic HRD Score Panel Done?
The NextGen geneCore Somatic Basic HRD Score Panel involves several precise laboratory steps to analyse your tumour tissue:
- Tissue preparation: Your FFPE tissue block is sectioned and processed for DNA extraction.
- Next-generation sequencing: Advanced NGS technology analyses the tumour DNA for genomic patterns.
- Bioinformatics analysis: Sophisticated computer algorithms calculate genomic instability scores.
- HRD score calculation: The final score is determined based on loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions.
- Report generation: Results are compiled into a comprehensive report for your oncologist.
How Should You Prepare for a NextGen geneCore Somatic Basic HRD Score Panel?
Preparation for this test is minimal since it uses previously collected tumour tissue:
- Submit histopathology report: The laboratory needs your original tissue diagnosis report for accurate analysis.
- No fasting required: This test does not require any dietary restrictions.
- Provide clinical history: Ensure your doctor has complete information about your cancer diagnosis and treatment history.
- Continue regular medications: No need to stop any current treatments unless specifically advised by your doctor.
Diseases that a NextGen geneCore Somatic Basic HRD Score Panel Can Help Detect
The NextGen geneCore Somatic Basic HRD Score Panel helps evaluate treatment options for several cancer types:
- High-grade serous ovarian cancer: Identifies patients suitable for PARP inhibitor maintenance therapy
- Other solid tumours with suspected HRD: Assesses genomic instability patterns for treatment planning
NextGen geneCore Somatic Basic HRD Score Panel/Packages that You Can Book With Metropolis Healthcare
Metropolis Healthcare offers comprehensive genetic testing options to support your cancer care journey:
|
Test/Package |
Purpose/Highlights |
|
Comprehensive analysis of homologous recombination repair genes |
|
|
BRCA2 or BRCA1 mutation test analysis in tumour tissue |
|
|
BRCA1 or BRCA2 mutation test for family members |
|
|
Protein expression analysis in tissue samples |
Frequently asked questions
Find quick answers to the most common questions about health tests, bookings, and reports.
Regular exercise, a balanced diet, avoiding smoking, maintaining a healthy weight, and managing stress all help reduce heart disease risk.
Common signs include irritability, trouble sleeping, headaches, difficulty concentrating, and muscle tension.
Ratings & Reviews
We're satisfying our customers every day since 1980.
Choose precision On time, every time!
- 98% on time collections with a 60 minutes promise
- Real-time tracking of phlebotomist arrival and report generation
- Fully digital report delivery—view from mobile or desktop instantly
- Continuous monitoring of turnaround times to ensure accuracy and speed
- Dedicated support team to resolve any delays or queries quickly
Why Metropolis Healthcare?
Metropolis has been present for over 40 years in the market.
Metropolis has a team of 200 senior pathologists and over 2000 technicians delivering diagnostic solutions in the areas of routine, semi specialty and super specialty domains like Oncology, Neurology, Gynaecology, Nephrology and many more.
0
Years of experience
170+
Advanced Labs
Trusted by
Leading Doctors & Hospitals
2,000+
Scientific Officers
Proficiency Testing
for Accurate Reports
Latest Blogs & News
Stay informed with our expert insights and updates.
About Us
Metropolis Healthcare is a leading diagnostic service provider in India. We are a team of dedicated professionals committed to ensuring you and your family receive the most accurate and timely healthcare solutions. We believe in making health care accessible, affordable and evidence-based. Our expert panel are equipped with the latest technology and manned by a certified team of over 4000+ technicians.
In diagnostic services, we have more than three decades of experience servicing diverse stakeholders health advantage packages for men, women and seniors, genetic fitness & corporation in over 650+ tests like Oncology, Neurology, Gynaecology, Haematology, and many more. Our diagnostic services are located in leading doctors and clinics and serve over 15+ cities in India.